Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups
Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
Novel Trispecific Antibody May Offer “Renewed Hope” in R/R Multiple Myeloma
Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
Anti-Angiogenesis Plus ICIs, Chemo Improve Frontline Efficacy in ES-SCLC
The addition of angiogenesis inhibition to immunochemotherapy for untreated extensive-stage small cell lung cancer did not significantly increase toxicity.
ASCT Shows No Significant MRD− Difference Vs Isa-KRd in Multiple Myeloma
Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.
FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer
Results from the phase 1a/b trial evaluating ADRX-0405 in various solid tumors, including gastric cancer, are expected to come in late 2025.
ZL-1310 Shows Promising Activity in Pretreated R/R ES-SCLC
Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.
Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups
Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.
FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer
The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
Olanzapine Combo Reduces Chemo-Induced Nausea, Vomiting in Breast Cancer
Patient-reported satisfaction was higher in patients with breast cancer treated with olanzapine vs those who underwent treatment with placebo.
HAIC Regimen Yields Long-Term Survival in Unresectable HCC
HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.
Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer
Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.
Teclistamab Shows Viability in Anti-BCMA Pretreated Multiple Myeloma
Prior BCMA-DT exposure was associated with a trend toward worse PFS outcomes and a lower likelihood of response in patients with multiple myeloma.
Advancing Treatment for EGFR Inhibitor–Associated Dermal Toxicities
ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.
IDH-Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML
Current data support prospective studies comparing IDH-triplet vs IDH-doublet therapies among patients with IDH-mutant acute myeloid leukemia.
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete
The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.
Partial-Breast Radiation Appears Effective, Safe in Early Breast Cancer
Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.
FDA OKs NGS Test for Tumor Profiling and as CDx for Sunvozertinib in NSCLC
The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.
YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors
Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.
FDA Approves SIR-Sphere Y-90 in HCC
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
Best Practices for the Medical Oncology Boards
A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.
The CHALLENGE Trial Helps Redefine Adjuvant Therapy With Exercise in CRC
The CHALLENGE trial in CRC studied structured exercise and demonstrated a DFS benefit comparable to or exceeding oxaliplatin chemotherapy.
New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma
Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.
[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer
No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.
Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer
Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.
Male Cancer Survivors in Physically Demanding Jobs Need More Support
Findings from a WeCanWork study showed that men who work laborious jobs need additional support during and after cancer treatment.
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
Advances in NSCLC Bring Excitement in the Lung Space
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
![No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F566910aff802a39d5d1afef401d33f429392d845-1200x886.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.")
